{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field b6ffc0fe-96dc-40be-b6ca-884179cd48d2 --><h2>Changes</h2><!-- end field b6ffc0fe-96dc-40be-b6ca-884179cd48d2 -->","summary":null,"htmlStringContent":"<!-- begin item 7bbda3d3-fb4b-4a07-8057-f86aaa035179 --><!-- begin field 33cacaa9-8888-4fb6-bec0-3695d4c0d8db --><p><strong>July to September 2018 </strong>— reviewed. A literature search was conducted in July 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. The Scenarios have been merged into one Scenario, and recommendations in the Management section have been updated in line with current literature. The section on Prescribing information has been updated and expanded.</p><!-- end field 33cacaa9-8888-4fb6-bec0-3695d4c0d8db --><!-- end item 7bbda3d3-fb4b-4a07-8057-f86aaa035179 -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"8751a04b-edf2-57ca-ad61-4fe9537814ba","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 487ad0b3-1a4a-4c9d-a04b-1d4921dda44f --><h3>Previous changes</h3><!-- end field 487ad0b3-1a4a-4c9d-a04b-1d4921dda44f -->","summary":null,"htmlStringContent":"<!-- begin item 6ba47aeb-2585-45b2-b31f-4f5ce455d45b --><!-- begin field 591c5330-a9da-45c7-a1fd-91b4f19f1e70 --><p><strong>January 2018</strong> — minor update. The section on the adverse effects of non-sedating antihistamines has been updated to reflect changes to the manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>May 2017 </strong>— minor update. Information regarding the expected increased risk of systemic adverse effects after co-treatment with CYP3A inhibitors, including cobicistat-containing products has been added to reflect an update to the manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>October 2015</strong> — minor update. The licensing information on mometasone (Nasonex<sup>®</sup>) has been amended in line with the manufacturer's Summary of Product Characteristics (SPC); it is now licensed for use in people from the age of 3 years (previously from 6 years onwards) and for the treatment of nasal polyps in adults 18 years of age and older.</p><p><strong>June 2015 </strong>— minor update. Information on the choice of intranasal corticosteroids has been updated to include the licensed ages. In addition, flunisolide has been removed as an option because it has been discontinued by the manufacturer.</p><p><strong>June 2014 </strong>— minor update. Typographical errors corrected, and the topic summary was reformatted.</p><p><strong>November 2012 </strong>— reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to clinical recommendations have been made.</p><p><strong>September 2012 </strong>— minor update. Ephedrine 0.5% nasal drops are no longer licensed for use in children younger than 12 years of age. Text and prescriptions have been updated.</p><p><strong>June 2012 </strong>— minor update. Typographical error corrected.</p><p><strong>January 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>August 2009 </strong>— minor update. Xylometazoline 0.05% nasal drops (Otrivine Child Nasal Drops<sup>®</sup>) are no longer licensed for use in children between 2 and 5 years of age. They can be prescribed for children who are 6 years of age and over. Issued in August 2009.</p><p><strong>May 2009 </strong>— minor formatting correction. Issued in June 2009.</p><p><strong>October 2007 to January 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The previous system of classifying a person with allergic rhinitis by the persistence and severity of their symptoms to determine management has been modified. Management is now divided into whether or not a person with symptoms of allergic rhinitis is presently on treatment, and this is reflected in the scenarios offered.</p><p><strong>July 2006 </strong>— minor update. Levocabastine products discontinued and prescriptions removed. Issued in July 2006.</p><p><strong>April 2006 </strong>— minor update. Montelukast now licensed for symptomatic relief of seasonal allergic rhinitis in people with asthma in whom montelukast is indicated. Text and prescriptions updated to reflect this. Issued in May 2006.</p><p><strong>January 2006 </strong>— minor update. Black triangle removed from desloratadine. Issued in February 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to include sodium cromoglicate eye drops for use in pregnancy. Issued in July 2005.</p><p><strong>December 2004 </strong>— rewritten. Validated in March 2005 and issued in April 2005.</p><p><strong>December 2001 </strong>— rewritten, replacing the previous topic <em>Allergic rhinitis/hay fever</em>. Validated in March 2002 and issued in April 2002.</p><p><strong>September 1998 </strong>— written.</p><!-- end field 591c5330-a9da-45c7-a1fd-91b4f19f1e70 --><!-- end item 6ba47aeb-2585-45b2-b31f-4f5ce455d45b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}